Quaternary Ammonium Compounds and Contact Dermatitis: A Review and Considerations During the COVID-19 Pandemic

Chidubem AV Okeke; Ramona Khanna; Alison Ehrlich

doi:10.2147/CCID.S410910

Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 16

Review

Quaternary Ammonium Compounds and Contact Dermatitis: A Review and Considerations During the COVID-19 Pandemic

Authors Okeke CAV , Khanna R, Ehrlich A

Received 16 March 2023

Accepted for publication 16 June 2023

Published 30 June 2023 Volume 2023:16 Pages 1721—1728

DOI https://doi.org/10.2147/CCID.S410910

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg

Download Article [PDF]

Chidubem AV Okeke,¹ Ramona Khanna,² Alison Ehrlich³

¹Department of Dermatology, Howard University College of Medicine, Washington, DC, USA; ²Georgetown University School of Medicine, Washington, DC, USA; ³Foxhall Dermatology, Washington, DC, USA

Correspondence: Chidubem AV Okeke, Department of Dermatology, Howard University College of Medicine, 520 W Street NW, Room 3035/3036, Washington, DC, USA, Email [email protected]

Abstract: The recent global pandemic has resulted in increased use of quaternary ammonium compounds (QACs). Currently, QACs are active ingredients in 292 disinfectants recommended by the US EPA for use against SARS-CoV-2. Among QACs, benzalkonium chloride (BAK), cetrimonium bromide (CTAB), cetrimonium chloride (CTAC), didecyldimethylammonium chloride (DDAC), cetrimide, quaternium-15, cetylpyridinium chloride (CPC), and benzethonium chloride (BEC) were all identified as potential culprits of skin sensitivity. Given their widespread utilization, additional research is needed to better classify their dermal effects and identify other cross-reactors. In this review, we aimed to expand our knowledge about these QACs to further dissect its potential allergic and irritant dermal effects on healthcare workers during COVID-19.

Keywords: patch test, systemic contact dermatitis, hypersensitivity, allergic contact dermatitis, COVID-19, healthcare

Introduction

Quaternary ammonium compounds (QACs) are active ingredients in 292 disinfectants recommended by the US EPA for use against SARS-CoV-2.¹ QACs are amphiphilic cationic surfactants that reduce interfacial tension through self-assembly behavior.² Their ability to denature cell proteins and disrupt cell membranes make them effective against a spectrum of organisms and essential components in hospital, industry and cosmetic formulations (see Table 1).^3,4 However, growing evidence suggests that exposure to these compounds may result in contact dermatitis (see Table 2).^5–9 Herein, this article explores the most frequently used QACs in both personal products and cleaning supplies and their association with contact dermatitis.

Table 1 No. of QAC-Containing Products in Online Databases

Table 2 Summary of Contact Dermatitis Cases Caused by QACs

Benzalkonium Chloride

Benzalkonium chloride (BAK) is marketed as a potent disinfectant and antiseptic³⁶ and reportedly an ingredient in approximately 20% of personal care products.²¹ It has the potential to penetrate milled smooth rubber gloves in conditions of prolonged exposure.³⁷ The most common sources of BAK exposure are ophthalmic eye drops, topical antiseptics, and cosmetics and various dental composites.^10,38 Though frequently used, the literature suggests that there has been an increasing rate of allergenicity associated with BAK since 1998.³⁹ A comparative study confirmed that as compared to other bis-QACs, BAK had caused significant damage to human epidermis models, demonstrating increased stratum corneum permeability and increased inflammatory cytokine mRNA expression.⁴⁰ Several case reports and retrospective studies have highlighted associations between irritant contact dermatitis (ICD) or allergic contact dermatitis (ACD) and BAK-containing products as well.^{5,21,39,41–43} Currently, healthcare workers are most likely to be exposed to BAK,¹⁰ making dental personnel an occupational subgroup with a high risk of BAK contact sensitivity.⁴⁴ Patients commonly present with eczematous rashes, eruptions or dermatitis,^9,41,45–47 noting clinical improvement with discontinued use of BAK-containing products.^9,41,48,49

Cetrimonium Bromide and Cetrimonium Chloride

Cetrimonium bromide (CTAB) is an effective bactericidal agent⁵⁰ with various purposes in cosmetic and personal care products. It is broadly utilized in formulations as an emulsifier, anti-static agent, and surfactant.^27,51,52 CTAB’s ability to penetrate and neutralize electrical charge on the hair surface has made it a favorable ingredient in hair care products, especially in conditioners.⁵³ Experimental studies using human cell types have reported CTAB’s ability to cause keratinocyte proliferation, sensitization and irritation.^54–56 Although relatively rare, cetrimonium bromide sensitivity upon skin contact has been reported to cause hyperpigmentation, eczema and skin swelling.^27,29,57

Cetrimonium chloride (CTAC) is an ingredient found in over 300 products listed on the Environmental Working Group (EWG) and CPID databases.⁵⁸ It is a constituent of a variety of household, pet, auto, and personal care products. In Europe, it can be found in haircare and cosmetic items at concentrations between 0.5 and 2.5% due to its potential irritancy.⁵⁹ There has been one case reported associating CTAC with contact dermatitis. The patient presented with pruritic dermatitis and had a strong positive patch tests to both benzalkonium chloride and cetrimonium chloride.¹³

Didecyldimethylammonium Chloride and Cetrimide

Didecyldimethylammonium chloride (DDAC) is a biocidal agent used in industrial and commercial products^60,61 and is listed as an ingredient in 142 brands on CPID.⁵⁸ There is a paucity of data evaluating DDAC toxicity; however, few studies have revealed potential irritancy and sensitivity associated with DDAC exposure. Following topical application on BALB/c mice, it was observed that DDAC significantly increased the activation of lymphocytes (T-cells, CD8 T-cells, B-cells, CD4 and dendritic cells).⁶² Another study confirmed a mixed-type hypersensitivity response upon DDAC exposure.⁶¹ Several case reports have highlighted DDAC-containing products as a source of contact dermatitis.^23–26,63 Mowitz & Ponten reported a case of a patient who developed oozing foot dermatitis after using a shoe refresher spray (containing 0.08% aq. DDAC).²⁶ Patch testing later confirmed ACD induced by DDAC exposure, and her symptoms healed upon discontinuation of the spray.

Cetrimide is an amalgam of tetradecyltrimethylammonium, dodecyltrimethylammonium, and hexadecyltrimethylammonium.⁶⁴ Its disruption of cell membranes makes it highly cytotoxic and therefore a common ingredient in cosmetic products as an antimicrobial agent.^28,64 Though considered rare, several cases have reported ACD associated with the use of cetrimide-containing antiseptics and cosmetic products.^{28–30,65–67} Documented clinical presentations include skin swelling, burning, vesicular rashes, necrosis and photosensitivity.^{28–31,68,69}

Quaternium-15, Cetylpyridinium Chloride, Benzethonium Chloride

There is limited research on healthcare-related reactions, such as contact dermatitis, associated with quaternium-15, cetylpyridinium chloride, and benzethonium chloride (BEC). Quaternium-15 is utilized in a wide variety of products as both a preservative and as an antistatic agent. Due to concerns about its release of formaldehyde, the Cosmetic Ingredient Review Expert Panel confirmed that it should only be used in concentrations below 0.2%.⁷⁰ An isolated case report described evidence of hand dermatitis with a positive patch test to both quaternium-15 and formaldehyde in a nurse that used a quaternium-15-containing lotion.⁷¹

Cetylpyridinium chloride (CPC) is used for its high antimicrobial activity^72,73 commonly utilized in oral hygiene products. CPC is also used as a constituent in rubber gloves, antiseptic products, mouth rinses and throat sprays.^33,72,74 Several case studies have reported sensitivity after CPC use resulting in either allergic contact dermatitis or irritant contact dermatitis.^33,75,76 Some manifestations of CPC induced contact dermatitis include swelling, pruritic rashes and burning flares.

Benzethonium chloride (BEC) is a synthetic quaternary amine. Allergic sensitization and irritation have been documented in a small number of patients who had known exposure to BEC,³⁵ but an evident association between contact dermatitis and BEC has not been well established. Common presentations of suspected contact dermatitis in BEC positive patch test patients include skin ulceration, well-defined erythema and vesicular rashes.³⁵ Due to its limited irritancy data, products containing less than 0.5% BEC may be considered safer than products comprised higher BEC concentrations.^48,77

Cross Reactivity Between QACs

Patch test reactions can reflect sensitivities between specific allergens. Cross reactors result from an immune response to compounds with similar chemical structures that might not otherwise be present.⁷⁸ Therefore, due to their structural similarity, QACs may exhibit cross-reactivity between one another.⁴⁹ According to the Camp database⁷⁹ and case reports,^13,21,48,49 benzalkonium chloride (BAK) cross reacts with 20 chemicals which include benzethonium chloride (BEC), cetrimide, cetrimonium bromide, cetrimonium chloride, and cetylpyridinium chloride, quaternium-15. A case report by Staniforth³² documented a patient who developed swollen hands and blistering skin upon use of a BAK containing plaster cast. Upon further evaluation, investigators found that the patient was also sensitive to a cream containing cetrimide. The patient’s patch tests were positive to both cetrimide and BAK, suggesting cross reactivity. Another patient, who had known exposure to BAK but no history of exposure to BEC, had positive patch tests to both compounds, suggesting possible cross reactivity.⁴⁸ An additional study described a patient with positive patch reactions and potential cross reactivity to both cetrimide and cetrimonium bromide after use of a tape containing cetrimide.²⁹ Overall, the existence and patterns of cross-reactivity between QACs are not fully delineated as evidence is limited.

QACs Impact in Healthcare Settings During COVID-19

The recent global pandemic due to SARS-CoV-2 and subsequent COVID-19 infection has resulted in increased QAC awareness. Studies evaluating QACs’ action against viral pathogens determined that QACs were effective disinfectants against SARS-CoV-2.^80–82

To prevent virus transmission, the US Environmental Protection Agency (EPA) released List N, a catalogue of disinfectants effective against Sars-COV-2.¹ Notably, QACs were the most widely represented active ingredients in all List N, found in 44% of the 538 products. In regard to skin testing, specifically, the compounds: benzalkonium chloride, didecyldimethylammonium chloride, cetrimonium bromide, cetrimide, cetylpyridinium chloride, and benzethonium chloride have all elicited a positive patch test causing photosensitive contact dermatitis, allergic contact dermatitis, and irritant contact dermatitis (see Table 2). Out of such compounds, a disinfectant containing 10% of didecyldimethylammonium chloride diluted 1:5 and 1:20 was the only instance of a negative patch test. Skin findings included ulcerations, well-defined erythema and vesicular rashes to compounds inducing a positive patch test.³⁵

Due to the presence of QACs in disinfectants and rubber gloves (latex and latex free), increased sanitary measures and personal protection equipment utilization during the pandemic has been thought to lead to increased irritation among healthcare workers. Currently, many surfactants, sterilization agents, antiseptics and preservatives used in household and healthcare environments contain QACs (see Table 3).^2,4,83 Routine surface cleaning and handwashing make healthcare workers highly susceptible to QAC’s potential allergic and irritant dermal effects compared to non-healthcare workers.^39,84 Several cases of contact dermatitis in response to the use of QAC-containing products have been reported in healthcare workers.^5,10,84–86 Many of these cases also demonstrated that avoidance of those products resulted in overall improvement of symptoms.^5,85

Table 3 Selected Listing of Common Household Products Containing QACs

Conclusion

In summary, quaternary ammonium compounds may cause irritancy and contact dermatitis, and should be used cautiously in patients with compromised skin barriers. Reported reactions include ulcerative skin lesions, hyperpigmentation, and erythema. Given their widespread utilization, additional research is needed to better classify their dermal effects and identify other cross-reactors. Healthcare workers’ have significantly increased exposure to QACs, but, considering the frequency and importance of hygiene and sterilization in a pandemic setting, it will be difficult to decrease utilization.

Disclosure

The authors report no conflicts of interest in this work.

References

1. United States Environmental Protection Agency. List N. disinfectants for use against SARS-CoV-2; 2022. Available from: https://www.epa.gov/pesticide-registration/list-n-disinfectants-coronavirus-covid-19. Accessed July 27, 2022.

2. Bures F. Quaternary ammonium compounds: simple in structure, complex in application. Top Curr Chem. 2019;377(3):14. doi:10.1007/s41061-019-0239-2

3. McKeen L. 1 - Introduction to Food Irradiation and Medical Sterilization. In: McKeen L, editor. The Effect of Sterilization on Plastics and Elastomers. 3rd ed. William Andrew Publishing; 2012:1–40.

4. Ioannou CJ, Hanlon GW, Denyer SP. Action of disinfectant quaternary ammonium compounds against staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(1):296–306. doi:10.1128/aac.00375-06

5. Shutty BG, Scheinman PL. occupationally induced allergic contact dermatitis to aerosolized quaternary ammonium compounds. Dermatitis. 2017;28(6):369. doi:10.1097/DER.0000000000000326

6. Osimitz TG, Droege W. Quaternary ammonium compounds: perspectives on benefits, hazards, and risk. Toxicol Res Applicat. 2021;5:23978473211049085. doi:10.1177/23978473211049085

7. Perrenoud D, Bircher A, Hunziker T, et al. Frequency of sensitization to 13 common preservatives in Switzerland. Swiss contact dermatitis research group. Contact Dermatitis. 1994;30(5):276–279. doi:10.1111/j.1600-0536.1994.tb00597.x

8. Warshaw EM, Ahmed RL, Belsito DV, et al. Contact dermatitis of the hands: cross-sectional analyses of North American Contact Dermatitis Group Data, 1994-2004. J Am Acad Dermatol. 2007;57(2):301–314. doi:10.1016/j.jaad.2007.04.016

9. Hamann CR, Duprat G, Dagrosa AT, Mann JA. “Desktop Dermatitis”: a case series of 7 patients with forearm contact dermatitis from frequent surface cleaning. Dermatitis. 2021;32(6):e104–e107. doi:10.1097/DER.0000000000000766

10. Dear K, Palmer A, Nixon R. Contact allergy and allergic contact dermatitis from benzalkonium chloride in a tertiary dermatology center in Melbourne, Australia. Contact Dermatitis. 2021;85:146–153. doi:10.1111/cod.13826

11. Stanford D, Georgouras K. Allergic contact dermatitis from benzalkonium chloride in plaster of Paris. Contact Dermatitis. 1996;35(6):371–372. doi:10.1111/j.1600-0536.1996.tb02427.x

12. Wong DA, Watson AB. Allergic contact dermatitis due to benzalkonium chloride in plaster of Paris. Australas J Dermatol. 2001;42(1):33–35. doi:10.1046/j.1440-0960.2001.00469.x

13. Zhang AJ, Boyd AH, Schlarbaum JP, Warshaw EM. Allergic contact dermatitis secondary to the use of a bandage impregnated with benzalkonium chloride. Contact Dermatitis. 2018;79(6):387–388. doi:10.1111/cod.13091

14. Amin KA, Belsito DV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis. 2006;55(5):280–285. doi:10.1111/j.1600-0536.2006.00927.x

15. Orsini D, D’Arino A, Pigliacelli F, Assorgi C, Latini A, Cristaudo A. Allergic contact dermatitis to dorzolamide and benzalkonium chloride. Postepy Dermatol Alergol. 2018;35(5):538–539. doi:10.5114/ada.2018.73859

16. Suchi ST, Gupta A, Srinivasan R. Contact allergic dermatitis and periocular depigmentation after using olapatidine eye drops. Indian J Ophthalmol. 2008;56(5):439–440. doi:10.4103/0301-4738.42431

17. Tartari F, Vincenzi C, Di Altobrando A, Bruni F, Neri I. Allergic contact dermatitis to benzalkonium chloride with erythema multiforme-like reaction in a child. Contact Dermatitis. 2020;82(6):397–399. doi:10.1111/cod.13481

18. Saw NK, Hindmarsh JR. Acute irritant reaction to an antiseptic bath emollient. Postgrad Med J. 2005;81(952):131–132. doi:10.1136/pgmj.2003.018564

19. Afzelius H, Thulin H. Allergic reactions to benzalkonium chloride. Contact Dermatitis. 1979;5(1):60. doi:10.1111/j.1600-0536.1979.tb05546.x

20. Ulicki M, Dendooven E, Aerts O. Triple relevant sensitization to didecyldimethylammonium chloride, benzalkonium chloride, and polyhexamethylene biguanide in a hospital cleaner. Contact Dermatitis. 2022;86(6):546–547. doi:10.1111/cod.14062

21. Isaac J, Scheinman PL. Benzalkonium chloride: an irritant and sensitizer. Dermatitis. 2017;28(6):346–352. doi:10.1097/DER.0000000000000316

22. Geier J, Lessmann H, Cevik N, Fuchs T, Buhl T. Patch testing with didecyldimethylammonium chloride. Contact Dermatitis. 2016;74(6):374–376. doi:10.1111/cod.12539

23. Geier J, Lessmann H, Krautheim A, Fuchs T. Airborne allergic contact dermatitis caused by didecyldimethylammonium chloride in a geriatric nurse. Contact Dermatitis. 2013;68(2):123–125. doi:10.1111/cod.12013

24. Ruiz Oropeza A, Fischer Friis U, Duus Johansen J. Occupational contact urticaria caused by didecyl dimethyl ammonium chloride. Contact Dermatitis. 2011;64(5):297–298. doi:10.1111/j.1600-0536.2011.01882.x

25. Dibo M, Brasch J. Occupational allergic contact dermatitis from N, N-bis(3-aminopropyl)dodecylamine and dimethyldidecylammonium chloride in 2 hospital staff. Contact Dermatitis. 2001;45(1):40. doi:10.1034/j.1600-0536.2001.045001040.x

26. Mowitz M, Ponten A. Foot dermatitis caused by didecyldimethylammonium chloride in a shoe refresher spray. Contact Dermatitis. 2015;73(6):374–376. doi:10.1111/cod.12456

27. Sharma VK, Bhatia R, Yadav CP. Clinical profile and allergens in pigmented cosmetic dermatitis and allergic contact dermatitis to cosmetics in India. Dermatitis. 2018;29(5):264–269. doi:10.1097/DER.0000000000000407

28. Lee JY, Wang BJ. Contact dermatitis caused by cetrimide in antiseptics. Contact Dermatitis. 1995;33(3):168–171. doi:10.1111/j.1600-0536.1995.tb00539.x

29. Engebretsen KA, Hald M, Johansen JD, Thyssen JP. Allergic contact dermatitis caused by an antiseptic containing cetrimide. Contact Dermatitis. 2015;72(1):60–61. doi:10.1111/cod.12303

30. Garg T, Agarwal S, Chander R, Singh A, Yadav P. Patch testing in patients with suspected cosmetic dermatitis: a retrospective study. J Cosmet Dermatol. 2018;17(1):95–100. doi:10.1111/jocd.12359

31. Inman JK. Cetrimide allergy presenting as suspected non-accidental injury. Br Med J. 1982;284(6313):385. doi:10.1136/bmj.284.6313.385

32. Staniforth P. Allergy to benzalkonium chloride in plaster of Paris after sensitisation to cetrimide. A case report. J Bone Joint Surg Br. 1980;62-B(4):500–501. doi:10.1302/0301-620X.62B4.7430233

33. Ponten A, Hamnerius N, Bruze M, et al. Occupational allergic contact dermatitis caused by sterile non-latex protective gloves: clinical investigation and chemical analyses. Contact Dermatitis. 2013;68(2):103–110. doi:10.1111/cod.12010

34. Hansen A, Buse AS, Wilke A, Skudlik C, John SM, Brans R. Sensitization to 1,3-diphenylguanidine: an underestimated problem in physicians and nurses using surgical gloves? Contact Dermatitis. 2021;84(3):207–208. doi:10.1111/cod.13713

35. Hirata Y, Yanagi T, Yamaguchi Y, et al. Ulcerative contact dermatitis caused by benzethonium chloride. Contact Dermatitis. 2017;76(3):188–190. doi:10.1111/cod.12682

36. Merchel Piovesan Pereira B, Tagkopoulos I. Benzalkonium chlorides: uses, regulatory status, and microbial resistance. Appl Environ Microbiol. 2019;85:13.

37. Kundsin RB, Walter CW. Investigations on adsorption of benzalkonium chloride U.S.P. by skin, gloves, and sponges. AMA Arch Surg. 1957;75(6):1036–1042. doi:10.1001/archsurg.1957.01280180168027

38. Mehdawi IM, Young A. 10 - Antibacterial composite restorative materials for dental applications. In: Barnes L, Cooper IR, editors. Biomaterials and Medical Device - Associated Infections. Woodhead Publishing; 2015:199–221.

39. Wentworth AB, Yiannias JA, Davis MD, Killian JM. Benzalkonium chloride: a known irritant and novel allergen. Dermatitis. 2016;27(1):14–20. doi:10.1097/DER.0000000000000160

40. Yamamoto M, Matsumura R, Hirata Y, Nagamune H. A comparative study of skin irritation caused by novel bis-quaternary ammonium compounds and commonly used antiseptics by using cell culture methods. Toxicol In Vitro. 2019;54:75–81. doi:10.1016/j.tiv.2018.09.009

41. Hann S, Hughes TM, Stone NM. Flexural allergic contact dermatitis to benzalkonium chloride in antiseptic bath oil. Br J Dermatol. 2007;157(4):795–798. doi:10.1111/j.1365-2133.2007.08134.x

42. Loo WJ, Alexandroff A, Burrows NP. Irritant dermatitis due to prolonged contact with Oilatum Plus. Br J Dermatol. 2003;148(1):171–172. doi:10.1046/j.1365-2133.2003.50891.x

43. Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Tursi A. Occupational irritant and allergic contact dermatitis among healthcare workers. Contact Dermatitis. 2002;46(2):101–107. doi:10.1034/j.1600-0536.2002.460208.x

44. Uter W, Lessmann H, Geier J, Schnuch A. Is the irritant benzalkonium chloride a contact allergen? A contribution to the ongoing debate from a clinical perspective. Contact Dermatitis. 2008;58(6):359–363. doi:10.1111/j.1600-0536.2008.01327.x

45. Lee SS, Hong DK, Jeong NJ, et al. Multicenter study of preservative sensitivity in patients with suspected cosmetic contact dermatitis in Korea. J Dermatol. 2012;39(8):677–681. doi:10.1111/j.1346-8138.2012.01551.x

46. Cusano F, Luciano S. Contact allergy to benzalkonium chloride and glutaraldehyde in a dental nurse. Contact Dermatitis. 1993;28(2):127. doi:10.1111/j.1600-0536.1993.tb03369.x

47. Placucci F, Benini A, Guerra L, Tosti A. Occupational allergic contact dermatitis from disinfectant wipes used in dentistry. Contact Dermatitis. 1996;35(5):306. doi:10.1111/j.1600-0536.1996.tb02397.x

48. Benjamin B, Chris F, Salvador G, Melissa G, Susan N. Visual and confocal microscopic interpretation of patch tests to benzethonium chloride and benzalkonium chloride. Skin Res Technol. 2012;18(3):272–277. doi:10.1111/j.1600-0846.2011.00577.x

49. Dao H Jr, Fricker C, Nedorost ST. Sensitization prevalence for benzalkonium chloride and benzethonium chloride. Dermatitis. 2012;23(4):162–166. doi:10.1097/DER.0b013e318260d78d

50. Dong W, Green J, Korza G, Setlow P. Killing of spores of Bacillus species by cetyltrimethylammonium bromide. J Appl Microbiol. 2019;126(5):1391–1401. doi:10.1111/jam.14242

51. Jairoun AA, Al-Hemyari SS, Shahwan M, Zyoud Se H. Analysis and Quantification of Alkyl (C12-22) trimethyl ammonium chloride content in cosmetics: regulatory compliance gap analysis. Cosmetics. 2021;8(4):103. doi:10.3390/cosmetics8040103

52. Becker LC, Bergfeld WF, Belsito DV, et al. Safety assessment of trimoniums as used in cosmetics. Int J Toxicol. 2012;31(6 Suppl):296S–341S. doi:10.1177/1091581812467378

53. Terol A, Gómez-Mingot M, Maestre SE, Prats S, Luis Todolí J, Paredes E. Simple and rapid analytical method for the simultaneous determination of cetrimonium chloride and alkyl alcohols in hair conditioners. Int J Cosmet Sci. 2010;32(1):65–72. doi:10.1111/j.1468-2494.2009.00553.x

54. Sauerova P, Pilgrova T, Pekar M, Hubalek Kalbacova M. Hyaluronic acid in complexes with surfactants: the efficient tool for reduction of the cytotoxic effect of surfactants on human cell types. Int J Biol Macromol. 2017;103:1276–1284. doi:10.1016/j.ijbiomac.2017.05.173

55. Bigliardi PL, Herron MJ, Nelson RD, Dahl MV. Effects of detergents on proliferation and metabolism of human keratinocytes. Exp Dermatol. 1994;3(2):89–94. doi:10.1111/j.1600-0625.1994.tb00053.x

56. Sanchez L, Mitjans M, Infante MR, Vinardell MP. Assessment of the potential skin irritation of lysine-derivative anionic surfactants using mouse fibroblasts and human keratinocytes as an alternative to animal testing. Pharm Res. 2004;21(9):1637–1641. doi:10.1023/b:pham.0000041459.63362.6f

57. Kataria V, Pandhi D, Bhattacharya SN. A cross-sectional study to analyze the clinical subtype, contact sensitization and impact of disease severity on quality of life and cost of illness in patients of hand eczema. Indian J Dermatol Venereol Leprol. 2020;86(6):663–668. doi:10.4103/ijdvl.IJDVL_333_18

58. DeLima Associates. Consumer product information database; 2022. Available from: https://www.whatsinproducts.com. Accessed December 11, 2022.

59. Commision Regulation (EU) No 866/2014. Amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on cosmetic products; 2014.

60. Walsh SE, Maillard JY, Russell AD, Catrenich CE, Charbonneau DL, Bartolo RG. Activity and mechanisms of action of selected biocidal agents on Gram-positive and -negative bacteria. J Appl Microbiol. 2003;94(2):240–247. doi:10.1046/j.1365-2672.2003.01825.x

61. Shane HL, Lukomska E, Kashon ML, Anderson SE. Topical application of the quaternary ammonium compound didecyldimethylammonium chloride activates type 2 innate lymphoid cells and initiates a mixed-type allergic response. Toxicol Sci. 2019;168(2):508–518. doi:10.1093/toxsci/kfz002

62. Shane HL, Lukomska E, Stefaniak AB, Anderson SE. Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide. J Immunotoxicol. 2017;14(1):204–214. doi:10.1080/1547691X.2017.1397826

63. Dejobert Y, Martin P, Piette F, Thomas P, Bergoend H. Contact dermatitis from didecyldimethylammonium chloride and bis-(aminopropyl)-lauryl amine in a detergent-disinfectant used in hospital. Contact Dermatitis. 1997;37(2):95–96. doi:10.1111/j.1600-0536.1997.tb00050.x

64. Aronson JK. Cetrimonium bromide and cetrimide. In: Meyler’s Side Effects of Drugs. 6th. Elsevier; 2016:224.

65. Kumar P, Paulose R. Patch testing in suspected allergic contact dermatitis to cosmetics. Dermatol Res Pract. 2014;2014:695387. doi:10.1155/2014/695387

66. Haidar Z. An adverse reaction to a topical antiseptic (cetrimide). Br J Oral Surg. 1978;16(1):86–91. doi:10.1016/s0007-117x(78)80061-4

67. Tomar J, Jain VK, Aggarwal K, Dayal S, Gupta S. Contact allergies to cosmetics: testing with 52 cosmetic ingredients and personal products. J Dermatol. 2005;32(12):951–955. doi:10.1111/j.1346-8138.2005.tb00880.x

68. August PJ. Cutaneous necrosis due to cetrimide application. Br Med J. 1975;1(5949):70. doi:10.1136/bmj.1.5949.70

69. Gathwala G, Agarwal N, Das K. Skin necrosis due to cetrimide application in a neonate. Indian J Pediatr. 2006;73(10):948. doi:10.1007/BF02859296

70. Becker LC. Quaternium-15. Int J Toxicol. 2017;36(5_suppl2):52S. doi:10.1177/1091581817717643

71. Cahill J, Nixon R. Allergic contact dermatitis to quaternium 15 in a moisturizing lotion. Australas J Dermatol. 2005;46(4):284–285. doi:10.1111/j.1440-0960.2005.00210.x

72. Sreenivasan PK, Haraszthy VI, Zambon JJ. Antimicrobial efficacy of 0.05% cetylpyridinium chloride mouthrinses. Lett Appl Microbiol. 2013;56(1):14–20. doi:10.1111/lam.12008

73. Tomino M, Nagano K, Hayashi T, Kuroki K, Kawai T. Antimicrobial efficacy of gutta-percha supplemented with cetylpyridinium chloride. J Oral Sci. 2016;58(2):277–282. doi:10.2334/josnusd.15-0620

74. Shima K, Tanizaki H, Endo Y, et al. Immediate hypersensitivity caused by cetylpyridinium chloride in a throat spray. Contact Dermatitis. 2015;73(4):248–249. doi:10.1111/cod.12418

75. Castelain M, Castelain PY. Allergic contact dermatitis from cetyl pyridinium chloride in latex gloves. Contact Dermatitis. 1993;28(2):118. doi:10.1111/j.1600-0536.1993.tb03360.x

76. Steinkjer B. Contact dermatitis from cetyl pyridinium chloride in latex surgical gloves. Contact Dermatitis. 1998;39(1):29–30. doi:10.1111/j.1600-0536.1998.tb05808.x

77. Liebert MA. 3 Final report on the safety assessment of benzethonium chloride and methylbenzethonium chloride. J Am Coll Toxicol. 1985;4(5):65–106. doi:10.3109/10915818509078687

78. Landeck L, Gonzalez E, Baden L, Neumann K, Schalock P. Positive concomitant test reactions to allergens in the standard patch test series. Int J Dermatol. 2010;49(5):517–519. doi:10.1111/j.1365-4632.2010.04309.x

79. The American Contact Dermatitis Society. Contact allergen management program (CAMP). Available from: https://www.contactderm.org/resources/acds-camp. Accessed December 11, 2022.

80. Ijaz MK, Whitehead K, Srinivasan V, et al. Microbicidal actives with virucidal efficacy against SARS-CoV-2. Am J Infect Control. 2020;48(8):972–973. doi:10.1016/j.ajic.2020.05.015

81. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. 2020;1(1):e10. doi:10.1016/S2666-5247(20)30003-3

82. Ogilvie BH, Solis-Leal A, Lopez JB, Poole BD, Robison RA, Berges BK. Alcohol-free hand sanitizer and other quaternary ammonium disinfectants quickly and effectively inactivate SARS-CoV-2. J Hosp Infect. 2020;108:142–145. doi:10.1016/j.jhin.2020.11.023

83. Ferreira JM. The quat advantage: quaternary ammonium chloride and its advantages in healthcare facilities. PDI Res Dev. 2015;2015:1–5.

84. Kadivar S, Belsito DV. Occupational dermatitis in health care workers evaluated for suspected allergic contact dermatitis. Dermatitis. 2015;26(4):177–183. doi:10.1097/DER.0000000000000124

85. De Quintana Sancho A, Raton JA, Eizaguirre X. Occupational allergic contact dermatitis caused by N, N-didecyl-N-methyl-poly(oxyethyl) ammonium propionate in a dental assistant. Contact Dermatitis. 2014;70(6):379–380. doi:10.1111/cod.12174

86. Bernstein JA, Stauder T, Bernstein DI, Bernstein IL. A combined respiratory and cutaneous hypersensitivity syndrome induced by work exposure to quaternary amines. J Allergy Clin Immunol. 1994;94(2 Pt 1):257–259. doi:10.1016/0091-6749(94)90048-5

Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]